Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT

Clinical Nuclear Medicine

Volumn 41, Issue 4, 2016, Pages 331-332

  Kanthan, Gowri L ^a   Drummond, James ^a   Schembri, Geoff Paul ^a   Izard, Michael A ^b,c   Hsiao, Edward ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Mater Hospital   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

68Ga PSMA PET CT; Prostate carcinoma; Thyroid adenoma

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; ORGANOMETALLIC COMPOUND;

ADOLESCENT; ADULT; ARTICLE; BIOPSY; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; RADIODIAGNOSIS; SUBTOTAL THYROIDECTOMY; THYROID ADENOMA; THYROID NODULE; ADENOMA; CARCINOMA; DIAGNOSTIC IMAGING; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; THYROID GLAND; X-RAY COMPUTED TOMOGRAPHY;

ADENOMA; CARCINOMA; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; THYROID GLAND; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84949448436     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001084     Document Type: Article

References (8)

1. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
2. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004; 6(6 Suppl):S13-S18.
3. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
4. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
5. Wang W, Tavora F, Sharma R, et al. PSMA expression in Schwannoma: a potential clinical mimicker of metastatic prostate carcinoma. Urol Oncol. 2009;27:525-528.
6. Demirci E, Ocak M, Kabasakal L, et al. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461-1462.
7. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumorassociated neovasculature. Cancer Res. 1999;59:3192-3198.
8. Verburg FA, Krohn T, Heinzel A, et al. First evidence of PSMA expression in differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42:1622-1623.